Skip to main content

Articles

Page 3 of 6

  1. Quantification of actinium-225 through gamma counter measurements, when there is no secular equilibrium between actinium-225 and its gamma emitting daughters bismuth-213 and/or francium-221, can provide valuab...

    Authors: Dayana Castillo Seoane, Marijke De Saint-Hubert, Stephen Ahenkorah, Clarita Saldarriaga Vargas, Maarten Ooms, Lara Struelens and Michel Koole
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:28
  2. The radiometal gallium-68 (68Ga) is increasingly used in diagnostic positron emission tomography (PET), with 68Ga-labeled radiopharmaceuticals developed as potential higher-resolution imaging alternatives to trad...

    Authors: Bryce J. B. Nelson, Jan D. Andersson, Frank Wuest and Sarah Spreckelmeyer
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:27
  3. 2-[18F]Fluoroethyltosylate ([18F]FEtOTs) is a well-known 18F-fluoroalkylating agent widely used to synthesize radiotracers for positron emission tomography. The widespread use of [18F]FEtOTs is due in part to its...

    Authors: Martha Sahylí Ortega Pijeira, Sofia Nascimento dos Santos, Yasniel Babi Araujo, André Luis Lapolli, Marcio Nardelli Wandermuren, Zalua Rodríguez Riera, Ivone Carvalho, Philip H. Elsinga and Emerson Soares Bernardes
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:26
  4. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Jun Toyohara, Mohammed Al-Qahtani, Ya-Yao Huang, Emiliano Cazzola, Sergio Todde, Shozo Furumoto, Renata Mikolajczak, Clemens Decristoforo, Nic Gillings, Min Yang, Raymond Reilly, Adriano Duatti, Antonia Denkova, Ralf Schirrmacher, Giuseppe Carlucci, Yann Seimbille…
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:25
  5. [177Lu]Lu-PSMA is used for the treatment of metastatic castration-resistant prostate cancer. For in-house productions, quality control methods are essential for ensuring product quality, and thus patient safety. ...

    Authors: Else A. Aalbersberg, Tammie T. Cao, Martine M. Geluk-Jonker and Jeroen J. M. A. Hendrikx
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:24
  6. With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent y...

    Authors: Alexander W. E. Sadler, Leena Hogan, Benjamin Fraser and Louis M. Rendina
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:21
  7. The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [68Ga]Ga-FAPI-46 is a new radiotrace...

    Authors: Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao and Maaz Zuhayra
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:20
  8. Myocardial perfusion imaging (MPI) is one of the most commonly performed investigations in nuclear medicine procedures. Due to the longer half-life of the emerging positron emitter copper-64 and its availabili...

    Authors: Norah AlHokbany, Ibrahim AlJammaz, Basem AlOtaibi, Yousif AlMalki, Bander AlJammaz and Subhani M. Okarvi
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:19
  9. The development of radiopharmaceuticals requires extensive evaluation before they can be applied in a diagnostic or therapeutic setting in Nuclear Medicine. Chemical, radiochemical, and pharmaceutical paramete...

    Authors: Aruna Korde, Renata Mikolajczak, Petra Kolenc, Penelope Bouziotis, Hadis Westin, Mette Lauritzen, Michel Koole, Matthias Manfred Herth, Manuel Bardiès, Andre F. Martins, Antonio Paulo, Serge K. Lyashchenko, Sergio Todde, Sangram Nag, Efthimis Lamprou, Antero Abrunhosa…
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:18
  10. The efficient management of hospital radiopharmacy is very important for a good workflow in nuclear medicine and essential to ensure the correct traceability of the radiopharmaceuticals administered to patient...

    Authors: Jesús Luis Gómez Perales
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:17
  11. Radionuclide therapy (RNT) has become a very important treatment modality for cancer nowadays. Comparing with other cancer treatment options, sufficient efficacy could be achieved in RNT with lower toxicity. β e...

    Authors: Runze Wang, Bernard Ponsard, Hubert Wolterbeek and Antonia Denkova
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:16
  12. Positron emission tomography (PET) is a powerful tool in medical imaging, especially in combination with the PET radionuclide fluorine-18 that possesses optimal characteristics. For labelling of biomolecules a...

    Authors: Carsten Sven Kramer, Luca Greiner, Klaus Kopka and Martin Schäfer
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:15
  13. This review presents the results of a survey conducted by the International Atomic Energy Agency on cyclotrons and related infrastructure used for radionuclide and radiopharmaceutical production which are supp...

    Authors: Miguel A. Avila-Rodriguez, Amir R. Jalilian, Aruna Korde, David Schlyer, Mohammad Haji-Saeid, Jose Paez and Saul Perez-Pijuan
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:14
  14. Tissue hypoxia is a pathological condition characterized by reducing oxygen supply. Hypoxia is a hallmark of tumor environment and is commonly observed in many solid tumors. Non-invasive imaging techniques lik...

    Authors: Arian Pérez Nario, Jenilee Woodfield, Sofia Nascimento dos Santos, Cody Bergman, Melinda Wuest, Yasniel Babí Araújo, André Luis Lapolli, Frederick G. West, Frank Wuest and Emerson Soares Bernardes
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:13
  15. Combining optical (fluorescence) imaging with nuclear imaging has the potential to offer a powerful tool in personal health care, where nuclear imaging offers in vivo functional whole-body visualization, and t...

    Authors: Anthony W. McDonagh, Brooke L. McNeil, Julie Rousseau, Ryan J. Roberts, Helen Merkens, Hua Yang, François Bénard and Caterina F. Ramogida
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:12
  16. The increasing incidence of cancer over the years is one of the most challenging problems in healthcare. As cancer progresses, the recruitment of several immune cells is triggered. Infiltration of tumor-associ...

    Authors: Bruna Fernandes, Paula Kopschina Feltes, Carolina Luft, Luiza Reali Nazario, Cristina Maria Moriguchi Jeckel, Ines F. Antunes, Philip H. Elsinga and Erik F. J. de Vries
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:11
  17. Noninvasive molecular imaging using peptides and biomolecules labelled with positron emitters has become important for detection of cancer and other diseases with PET (positron emission tomography). The positr...

    Authors: Raphaël Hoareau, Tore Bach-Gansmo, Paul Cumming and Dag Erlend Olberg
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:10
  18. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Emerson Bernardes, Peter Caravan, R. Michael van Dam, Winnie Deuther-Conrad, Beverley Ellis, Shozo Furumoto, Benjamin Guillet, Ya-Yao Huang, Hongmei Jia, Peter Laverman, Zijing Li, Zhaofei Liu, Filippo Lodi, Yubin Miao, Lars Perk, Ralf Schirrmacher…
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:9
  19. Recent advances in nanotechnology have offered new hope for cancer detection, prevention, and treatment. Nanomedicine, a term for the application of nanotechnology in medical and health fields, uses nanopartic...

    Authors: Martha Sahylí Ortega Pijeira, Herlys Viltres, Jan Kozempel, Michal Sakmár, Martin Vlk, Derya İlem-Özdemir, Meliha Ekinci, Seshasai Srinivasan, Amin Reza Rajabzadeh, Eduardo Ricci-Junior, Luciana Magalhães Rebelo Alencar, Mohammed Al Qahtani and Ralph Santos-Oliveira
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:8
  20. Prosthetic approach for the radiolabeling of biologics with fluorine-18 is a robust strategy and has been employed for many years. It requires fast, biocompatible and selective reactions suited to these fragil...

    Authors: Mylène Richard, Françoise Hinnen and Bertrand Kuhnast
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:7
  21. The GMP-compliant production of radiopharmaceuticals has been performed using disposable units (cassettes) with a dedicated synthesis module. To expand this “plug ‘n’ synthesize” principle to a broader scope o...

    Authors: Jan Wenz, Felix Arndt and Samuel Samnick
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:6
  22. Flumazenil (FMZ) is a functionally silent imidazobenzodiazepine which binds to the benzodiazepine binding site of approximately 75% of the brain γ-aminobutyric acid-A receptors (GABAARs). Positron Emission Tomogr...

    Authors: Thibault Gendron, Gianluca Destro, Natan J. W. Straathof, Jeroen B. I. Sap, Florian Guibbal, Charles Vriamont, Claire Caygill, John R. Atack, Andrew J. Watkins, Christopher Marshall, Rebekka Hueting, Corentin Warnier, Véronique Gouverneur and Matthew Tredwell
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:5
  23. Receptor-interacting protein 1 kinase (RIPK1) is a key enzyme in the regulation of cellular necroptosis. Recently, cyclohexyl (5-(2-acetamidobenzo[d]thiazol-6-yl)-2-methylpyridin-3-yl)carbamate (PK68, 5) has been...

    Authors: Tomoteru Yamasaki, Katsushi Kumata, Atsuto Hiraishi, Yiding Zhang, Hidekatsu Wakizaka, Yusuke Kurihara, Nobuki Nengaki and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:4
  24. Pretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-...

    Authors: Hugo Helbert, Emily M. Ploeg, Douwe F. Samplonius, Simon N. Blok, Ines F. Antunes, Verena I. Böhmer, Gert Luurtsema, Rudi A. J. O. Dierckx, Ben L. Feringa, Philip H. Elsinga, Wiktor Szymanski and Wijnand Helfrich
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:3
  25. The need for a stability evaluation of [18F]FDG is evident. The main purpose of this study was to make recommendations for determining the shelf life based on the available stability literature and our own two-ce...

    Authors: Jes G. Holler, Børge Renmælmo and Richard Fjellaksel
    Citation: EJNMMI Radiopharmacy and Chemistry 2022 7:2
  26. As 225Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures. The determination of radiochemical pu...

    Authors: James M. Kelly, Alejandro Amor-Coarasa, Elizabeth Sweeney, Justin J. Wilson, Patrick W. Causey and John W. Babich
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:38
  27. Terbium-155 [T1/2 = 5.32 d, Eγ = 87 keV (32%) 105 keV (25%)] is an interesting radionuclide suitable for single photon emission computed tomography (SPECT) imaging with potential application in the diagnosis of o...

    Authors: C. Favaretto, Z. Talip, F. Borgna, P. V. Grundler, G. Dellepiane, A. Sommerhalder, H. Zhang, R. Schibli, S. Braccini, C. Müller and N. P. van der Meulen
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:37
  28. Prostate-specific membrane antigen is overexpressed in prostate cancer and it is considered a good target for positron emission tomography/computed tomography imaging of primary cancer and recurrent/metastatic...

    Authors: Costantina Maisto, Anna Morisco, Roberta de Marino, Elisabetta Squame, Valentina Porfidia, Laura D’Ambrosio, Daria Di Martino, Paolo Gaballo, Michela Aurilio, Monica Buonanno, Aureliana Esposito, Marco Raddi and Secondo Lastoria
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:36
  29. Nanocolloidal human serum albumin radiolabelled with 99mTc provides a diagnostic radiopharmaceutical for sentinel node lymphoscintigraphy. NanoHSA (Nanotop), a commercially available kit, enables the simple prepa...

    Authors: Ruslan Cusnir, Michel Leresche, Claude Pilloud and Marietta Straub
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:35
  30. This guideline on molar activity (Am) and specific activity (As) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe t...

    Authors: Gert Luurtsema, Verena Pichler, Salvatore Bongarzone, Yann Seimbille, Philip Elsinga, Antony Gee and Johnny Vercouillie
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:34
  31. Positron emission tomography (PET) has become an invaluable tool for drug discovery and diagnosis. The positron-emitting radionuclide fluorine-18 is frequently used in PET radiopharmaceuticals due to its advan...

    Authors: Javier Ajenjo, Gianluca Destro, Bart Cornelissen and Véronique Gouverneur
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:33

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2022 7:1

  32. The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

    Authors: Francisco Alves, Inês F. Antunes, Emiliano Cazzola, Frederik Cleeren, Bart Cornelissen, Antonia Denkova, Jonathan Engle, Alain Faivre-Chauvet, Nic Gillings, Jeroen J. M. A. Hendrikx, Amir R. Jalilian, Nicholas P. van der Meulen, Renata Mikolajczak, Oliver C. Neels, Maroor R. A. Pillai, Raymond Reilly…
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:31
  33. The aluminium-[18F]fluoride ([18F]AlF) radiolabelling method combines the favourable decay characteristics of fluorine-18 with the convenience and familiarity of metal-based radiochemistry and has been used to pa...

    Authors: Stephen J. Archibald and Louis Allott
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:30

    The Correction to this article has been published in EJNMMI Radiopharmacy and Chemistry 2021 6:32

  34. Elevated kidney uptake in insulinoma patients remains a major limitation of radiometallated exendin-derived ligands of the glucagon-like peptide 1 receptor (GLP-1R). Based on the previously published potent GL...

    Authors: Veronika Barbara Felber and Hans-Jürgen Wester
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:29
  35. Fibroblast activation protein (FAP) is overexpressed in the stroma of many types of cancer. [18F]AlF-FAPI-74 is a positron emission tomography tracer with high selectivity for FAP, which has already shown high ac...

    Authors: Sadahiro Naka, Tadashi Watabe, Thomas Lindner, Jens Cardinale, Kenta Kurimoto, Melissa Moore, Mitsuaki Tatsumi, Yuriko Mori, Eku Shimosegawa, Frank Valla Jr., Hiroki Kato and Frederik L. Giesel
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:28
  36. Patients with chronic kidney disease (CKD) may need to have their radiopharmaceutical dosage adjusted to prevent adverse effects and poor outcomes, but there are few recommendations on radiopharmaceutical dosi...

    Authors: Nanno Schreuder, Iris de Romijn, Pieter L. Jager, Jos G. W. Kosterink and Eugène P. van Puijenbroek
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:27
  37. Cancer-associated fibroblasts are found in the stroma of epithelial tumors. They are characterized by overexpression of the fibroblast activation protein (FAP), a serine protease which was already proven as at...

    Authors: Thomas Lindner, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Walter Mier, Jens Cardinale, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus and Uwe Haberkorn
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:26
  38. Epidermal growth factor receptors (EGFR) are overexpressed on many head and neck squamous cell carcinoma (HNSCC). Radioimmunotherapy (RIT) with F(ab')2 of the anti-EGFR monoclonal antibody panitumumab labeled wit...

    Authors: Anthony Ku, Misaki Kondo, Zhongli Cai, Jalna Meens, Min Rong Li, Laurie Ailles and Raymond M. Reilly
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:25
  39. [18F]MC225 is a radiotracer for imaging P-glycoprotein (P-gp) function at the blood-brain barrier. The P-gp function can be altered due to different factors, for instance, decreased P-gp function has been describ...

    Authors: Lara Garcia-Varela, Khaled Attia, John Carlo Sembrano, Olivier Jacquet, Inês F. Antunes, Chantal Kwizera, Ton J. Visser, Rudi A. J. O. Dierckx, Philip H. Elsinga and Gert Luurtsema
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:24
  40. [18F]Fluoromisonidazole ([18F]FMISO) and 1-[18F]fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridine-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol ([18F]PM-PBB3 or [18F]APN-1607) are clinically used ra...

    Authors: Takayuki Ohkubo, Yusuke Kurihara, Masanao Ogawa, Nobuki Nengaki, Masayuki Fujinaga, Wakana Mori, Katsushi Kumata, Masayuki Hanyu, Kenji Furutsuka, Hiroki Hashimoto, Kazunori Kawamura and Ming-Rong Zhang
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:23
  41. [68Ga]Ga-NeoB is a novel DOTA-coupled Gastrin Releasing Peptide Receptor (GRPR) antagonist with high affinity for GRPR and good in vivo stability. This study aimed at (1) the translation of preclinical results to...

    Authors: Marc Pretze, Laura Reffert, Steffen Diehl, Stefan O. Schönberg, Carmen Wängler, Peter Hohenberger and Björn Wängler
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:22
  42. The radiofluorinated levodopa analogue 6-[18F]F-l-DOPA (3,4-dihydroxy-6-18F-l-phenylalanine) is a commonly employed radiotracer for PET/CT imaging of multiple oncological and neurological indications. An unusuall...

    Authors: Valdemar L. Andersen, Mikkel A. Soerensen, Johan Hygum Dam, Niels Langkjaer, Henrik Petersen, Dirk Andreas Bender, Dan Fugloe and Tri Hien Viet Huynh
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:21
  43. The translocator protein 18 kDa is recognised as an important biomarker for neuroinflammation due to its soaring expression in microglia. This process is common for various neurological disorders. DPA-714 is a...

    Authors: Klaudia A. Cybulska, Vera Bloemers, Lars R. Perk and Peter Laverman
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:20
  44. In the frame of “precision medicine”, the scandium radionuclides have recently received considerable interest, providing personalised adjustment of radiation characteristics to optimize the efficiency of medic...

    Authors: R. Mikolajczak, S. Huclier-Markai, C. Alliot, F. Haddad, D. Szikra, V. Forgacs and P. Garnuszek
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:19
  45. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Ângela C. B. Neves, Ivanna Hrynchak, Inês Fonseca, Vítor H. P. Alves, Mariette M. Pereira, Amílcar Falcão and Antero J. Abrunhosa
    Citation: EJNMMI Radiopharmacy and Chemistry 2021 6:18

    The original article was published in EJNMMI Radiopharmacy and Chemistry 2021 6:11

EJNMMI Reports - Kindly explore our collections here

Topical Collections about latest and interesting topics in EJNMMI Radiopharmacy and Chemistry are available at: https://link.springer.com/journal/41824/collections

EANM'24 - Future Congress!

EANM'24 banner horizontal

Future Congress

37th Annual Congress of the European Association of Nuclear Medicine

October 19 – 23, 2024
Hamburg, Germany


CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/

EJNMMI Journal Family and EANM Springer Award

New Content Item

EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.


Do you want to publish your paper open access?

Details of the OpenChoice option in EJNMMI are available in the submission guidelines.

If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.

Please check the agreement details by participating country here.